0001213900-23-044083.txt : 20230530 0001213900-23-044083.hdr.sgml : 20230530 20230530170645 ACCESSION NUMBER: 0001213900-23-044083 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230525 FILED AS OF DATE: 20230530 DATE AS OF CHANGE: 20230530 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fedeli Fabiana CENTRAL INDEX KEY: 0001961902 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39082 FILM NUMBER: 23977561 MAIL ADDRESS: STREET 1: C/O RELMADA THERAPEUTICS, INC. STREET 2: 2222 PONCE DE LEON BLVD, 3RD FLOOR CITY: CORAL GABLES STATE: FL ZIP: 33134 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: RELMADA THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001553643 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 455401931 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2222 PONCE DE LEON BLVD. 3RD FLOOR CITY: CORAL GABLES STATE: FL ZIP: 33134 BUSINESS PHONE: 646 876 3459 MAIL ADDRESS: STREET 1: 2222 PONCE DE LEON BLVD. 3RD FLOOR CITY: CORAL GABLES STATE: FL ZIP: 33134 FORMER COMPANY: FORMER CONFORMED NAME: CAMP NINE, INC. DATE OF NAME CHANGE: 20120706 4 1 ownership.xml X0407 4 2023-05-25 0 0001553643 RELMADA THERAPEUTICS, INC. RLMD 0001961902 Fedeli Fabiana C/O RELMADA THERAPEUTICS, INC. 2222 PONCE DE LEON BLVD, 3RD FLOOR CORAL GABLES, FL 33134 1 0 0 0 0 Stock Option (right to buy) 4.22 2023-05-25 4 A 0 200000 0 A 2024-01-12 2033-01-12 Common Stock 200000 200000 D The option grant was approved by the Board of Directors of the Company on January 12, 2023, subject to shareholder approval of an amendment to the Company's 2021 Equity Incentive Plan, as amended (the "Plan"), increasing the number of shares of Common Stock available for the grant of awards under the Plan in an amount sufficient to cover this option grant. Shareholder approval was received for such amendment on May 25, 2023, at the 2023 Annual Meeting of the Company's shareholders. 25% of the option vests on the first anniversary of the date grant and the remaining 75% in equal increments of 6.25% of the total options at the end of each three-month interval over the following three year period. /s/ Fabiana Fedeli 2023-05-30